Drug Discovery
ByIndian Biopharma Faces Freight Surge Amid US-Iran Escalation
India’s biopharma sector confronts $300-500M export losses as US-Iran war disrupts Gulf shipping, spiking container surcharges to $3,500–$5,000…
What broader implications does Zealand Pharma’s petrelintide trial setback raise for the GLP-1 obesity market?
Trial Context Recap ZUPREME-1 delivered 10.7% peak weight loss over 42 weeks across 493 patients, surpassing placebo but…
The $10B+ Pharma Titans of 2025: Fortress Builders or House of Cards?
In 2025, only nine pharmaceutical brands crossed the $10 billion revenue threshold, collectively generating $125B+ while representing 25% of global pharma sales—yet their…
How Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?
Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market share via Mounjaro/Zepbound ($39.5B 2025 revenue)…
J&J’s $1 Billion Firefly Bio Buy: Has Big Pharma Finally Found a Way to Drug the ‘Undruggable’ KRAS?
Key Highlights A Novel Modality for a Notoriously Hard Target At the center of the acquisition is Firefly…
Can a Single Injection Change Everything? Novartis’s Itvisma Wins EU Approval for Broader SMA Population
Key Highlights Closing a Long-Standing Treatment Gap Itvisma’s approval extends gene replacement therapy to an SMA population that…
